Literature DB >> 24085499

The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Francesco Giammarile1, Naomi Alazraki, John N Aarsvold, Riccardo A Audisio, Edwin Glass, Sandra F Grant, Jolanta Kunikowska, Marjut Leidenius, Valeria M Moncayo, Roger F Uren, Wim J G Oyen, Renato A Valdés Olmos, Sergi Vidal Sicart.   

Abstract

PURPOSE: The accurate harvesting of a sentinel node in breast cancer includes a sequence of procedures with components from different medical specialities, including nuclear medicine, radiology, surgical oncology and pathology. The aim of this document is to provide general information about sentinel lymph node detection in breast cancer patients.
METHODS: The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have written and approved these guidelines to promote the use of nuclear medicine procedures with high quality. The final result has been discussed by distinguished experts from the EANM Oncology Committee, the SNMMI and the European Society of Surgical Oncology (ESSO).
CONCLUSION: The present guidelines for nuclear medicine practitioners offer assistance in optimizing the diagnostic information from the SLN procedure. These guidelines describe protocols currently used routinely, but do not include all existing procedures. They should therefore not be taken as exclusive of other nuclear medicine modalities that can be used to obtain comparable results. It is important to remember that the resources and facilities available for patient care may vary.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085499     DOI: 10.1007/s00259-013-2544-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  138 in total

1.  Radiation safety with breast sentinel node biopsy.

Authors:  S L Stratmann; T M McCarty; J A Kuhn
Journal:  Am J Surg       Date:  1999-12       Impact factor: 2.565

2.  Radiation safety considerations for sentinel node techniques.

Authors:  E C Glass; J E Basinski; D L Krasne; A E Giuliano
Journal:  Ann Surg Oncol       Date:  1999 Jan-Feb       Impact factor: 5.344

3.  The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer.

Authors:  Iris M C van der Ploeg; Omgo E Nieweg; Bin B R Kroon; Emiel J T Rutgers; Marie-Jeanne T F D Baas-Vrancken Peeters; Wouter V Vogel; Cornelis A Hoefnagel; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-13       Impact factor: 9.236

4.  Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy.

Authors:  Paolo Veronesi; Oreste Gentilini; Julia Rodriguez Fernandez; Francesca Magnoni
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

5.  Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a phantom study with SPECT/CT and ICRP-103 recommendations.

Authors:  Martin Law; Wai-Han Ma; Raymond Leung; Steve Li; Kwong-Kuen Wong; Wai-Yin Ho; Ava Kwong
Journal:  Eur J Radiol       Date:  2012-03-02       Impact factor: 3.528

6.  Sentinel lymphadenectomy in breast cancer.

Authors:  A E Giuliano; R C Jones; M Brennan; R Statman
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

7.  Dynamic lymphoscintigraphy to identify the sentinel and satellite nodes.

Authors:  A Taylor; D Murray; S Herda; J Vansant; N Alazraki
Journal:  Clin Nucl Med       Date:  1996-10       Impact factor: 7.794

8.  Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial.

Authors:  Jean-François Rodier; Michel Velten; Marc Wilt; Pierre Martel; Gwanaël Ferron; Véronique Vaini-Elies; Hervé Mignotte; Alain Brémond; Jean-Marc Classe; François Dravet; Thierry Routiot; Christine Tunon de Lara; Antoine Avril; Gérard Lorimier; Eric Fondrinier; Gilles Houvenaeghel; Sandrine Avigdor
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

9.  Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients?

Authors:  Alice Chung; Jeanne Yu; Michelle Stempel; Sujata Patil; Hiram Cody; Leslie Montgomery
Journal:  Ann Surg Oncol       Date:  2008-08-08       Impact factor: 5.344

10.  Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases.

Authors:  Umberto Veronesi; Viviana Galimberti; Giovanni Paganelli; Patrick Maisonneuve; Giuseppe Viale; Roberto Orecchia; Alberto Luini; Mattia Intra; Paolo Veronesi; Pietro Caldarella; Giuseppe Renne; Nicole Rotmensz; Claudia Sangalli; Luciana De Brito Lima; Marco Tullii; Stefano Zurrida
Journal:  Eur J Cancer       Date:  2009-01-06       Impact factor: 9.162

View more
  43 in total

Review 1.  Sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma: current status and unresolved challenges.

Authors:  Christina Bluemel; Domenico Rubello; Patrick M Colletti; Remco de Bree; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-28       Impact factor: 9.236

2.  Fluorescent radiocolloids: are hybrid tracers the future for lymphatic mapping?

Authors:  Sergi Vidal-Sicart; Fijs W B van Leeuwen; Nynke S van den Berg; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-22       Impact factor: 9.236

3.  Grade 3 anaphylactic shock after administration of [99mTc]-labeled nanocolloidal albumin (Nanocoll®) for sentinel node scintigraphy.

Authors:  Andrea Skanjeti; Caroline Darcissac; Coline Jaulent; Jérôme Nicolas; François Hallouard; Isabelle Morelec; Marc Fraysse; Jérémie Tordo; Francesco Giammarile; Pierre-Adrien Bolze; Anthony Dhomps
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-16       Impact factor: 9.236

4.  Joint SNMMI and EANM guideline for small-bowel and colon transit: an important step towards long-awaited standardization.

Authors:  Giuliano Mariani; Italia Paglianiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03       Impact factor: 9.236

5.  Response to comment by Aprile et al.: the EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  F Giammarile; N Alazraki; J N Aarsvold; R A Audisio; E Glass; S F Grant; J Kunikowska; M Leidenius; V M Moncayo; R F Uren; W J Oyen; R A Valdés Olmos; S Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-26       Impact factor: 9.236

6.  Comment on: the EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  Carlo Aprile; Federica E Buroni; Lorenzo Lodola; Marco G Persico
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-26       Impact factor: 9.236

7.  Multimodal US-gamma imaging using collaborative robotics for cancer staging biopsies.

Authors:  Marco Esposito; Benjamin Busam; Christoph Hennersperger; Julia Rackerseder; Nassir Navab; Benjamin Frisch
Journal:  Int J Comput Assist Radiol Surg       Date:  2016-08-09       Impact factor: 2.924

8.  Radioguided surgery with 68Ga-DOTATATE for patients with neuroendocrine tumors.

Authors:  Valentina Ambrosini; Stefano Fanti
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

9.  Quality Indicators for Sentinel Lymph Node Biopsy in Breast Cancer: Applicability and Clinical Relevance in a Non-screened Population.

Authors:  Sanjit Kumar Agrawal; Sachin Suresh Shenoy; Nikhil Nalawade; Soumtira Shankar Datta; Soumendranath Roy; Sanjoy Chatterjee; Indu Arun; Rosina Ahmed
Journal:  Indian J Surg Oncol       Date:  2017-08-21

10.  Pre-operative sentinel lymph node localization in breast cancer with superparamagnetic iron oxide MRI: the SentiMAG Multicentre Trial imaging subprotocol.

Authors:  Joost J Pouw; Maarten R Grootendorst; Roland Bezooijen; Caroline A H Klazen; Wieger I De Bruin; Joost M Klaase; Margaret A Hall-Craggs; Michael Douek; Bennie Ten Haken
Journal:  Br J Radiol       Date:  2015-10-22       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.